<DOC>
	<DOCNO>NCT02311556</DOCNO>
	<brief_summary>This study design evaluate whether advanced magnetic resonance imaging ( MRI ) techniques dynamic susceptibility-weighted contrast-enhanced perfusion MRI may use predict treatment response brain metastasis radiosurgery .</brief_summary>
	<brief_title>Response Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<criteria>Patient must newly diagnose brain metastasis visible brain MRI . A biopsy lesion require long patient biopsyproven malignancy elsewhere clinician deems lesion metastatic . At least one brain metastasis must ≥ 1cm allow adequate quantitative imaging measurement DSCPMR . Patient must clinically eligible elect treat GK alone without WBRT . Patient must ≥ 18 year age . Patient must Karnofsky Performance Status ( KPS ) least 60 Patient may part clinical trial ( long local treatment beyond GK WBRT local therapy indicate brain ) imaging study . Patient legally authorize representative must able understand willing sign write informed consent document . Patient must medical contraindication MRI ( e.g. , unsafe foreign metallic implant , incompatible pacemaker , inability lie still long period , severe endstage kidney disease hemodialysis ) . Patient must pregnant breastfeeding . Patient must estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 . Patient must melanoma . Patient must hemorrhagic lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>